Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.79 |
| ▸ | DRD4 | P21917 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041313 | 0.97 | DRD4 (0.75) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| SCHEMBL6907364 | 0.89 | HTR2A (1.00) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| SCHEMBL7516300 | 0.89 | HTR2A (1.00) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL8552262 | 0.88 | HTR2A (0.98) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| Bromide SCHEMBL8553366 | 0.84 | HTR2A (0.91) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| SCHEMBL8552863 | 0.84 | HTR2A (0.87) | HTR2ADRD4MEN1KMT2ACHRM2 | |
| SCHEMBL3730571 | 0.77 | DRD4 (0.48) | HTR2ADRD4KCNH2 | |
| SCHEMBL3740900 | 0.77 | DRD4 (0.49) | HTR2ADRD4TSHR | |
| SCHEMBL15849937 | 0.76 | ALDH1A1 (0.47) | HTR2ADRD4MEN1KMT2ATSHR | |
| SCHEMBL13041314 | 0.75 | DRD4 (0.47) | HTR2ADRD4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | claimed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | HSD11B1, HSD3B1, HSD17B1 | HTR2A 1578/4885DRD4 2295/4885MEN1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.